Chief legal officer exits BridgeBio Oncology (NASDAQ: BBOT) role

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. disclosed that its Chief Legal Officer, Nebojsa Obradovic, is no longer serving in that role, effective August 11, 2025. This Form 4 is described as a voluntary "exit" report, filed to note that the reporting person is no longer subject to Section 16 insider reporting requirements.

The filing states that the reporting person had no transactions in the company’s securities requiring disclosure in this report and that no securities are beneficially owned following this change.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 08/11/2025 - 05:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Obradovic Nebojsa

(Last) (First) (Middle)

C/O HELIX ACQUISITION CORP. II

200 CLARENDON STREET, 52ND FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This is a voluntary "exit" report, filed solely to report that the Reporting Person is no longer the Issuer's Chief Legal Officer, effective as of August 11, 2025, and therefore is no longer subject to Section 16 reporting. The Reporting Person did not have any transactions in the Issuer's securities requiring disclosure in this voluntary "exit" report. No securities are beneficially owned.

	/s/ Nebojsa Obradovic	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does this Form 4 filing for HLXB/BridgeBio Oncology report?

This Form 4 is a voluntary "exit" report stating that Nebojsa Obradovic is no longer the Chief Legal Officer of BridgeBio Oncology Therapeutics, Inc. and is therefore no longer subject to Section 16 reporting.

When did the Chief Legal Officer leave BridgeBio Oncology Therapeutics, Inc. (BBOT)?

The filing states that the reporting person is no longer the issuer's Chief Legal Officer, effective as of August 11, 2025.

Were any BridgeBio Oncology (BBOT) share transactions reported in this Form 4?

No. The report explicitly states that the reporting person did not have any transactions in the issuer's securities requiring disclosure in this voluntary exit report.

Does the reporting person still own BridgeBio Oncology Therapeutics, Inc. securities?

The remarks section states that no securities are beneficially owned by the reporting person following the change in role.

Why is this Form 4 described as a voluntary exit report for BBOT?

It is described as a voluntary "exit" report because it is filed solely to report that the person is no longer the issuer's Chief Legal Officer and thus is no longer subject to Section 16 insider reporting obligations.

Is this Form 4 filed by more than one reporting person for BridgeBio Oncology?

No. The Form indicates that it is filed by one reporting person, identified as Nebojsa Obradovic.